

1 **DOI:** <https://doi.org/10.47391/JPMA.638>

2
3 **Ivabradine effects on heart rate and quality of life among chronic**
4 **heart failure patients**

5
6 **Fawad Farooq, Nida Imran, Mahwish Abbas**

7 National Institute of Cardiovascular Diseases, Karachi, Pakistan

8 **Correspondence:** Fawad Farooq. **Email:** farooqfawwad@gmail.com

9
10 **Abstract**

11 **Objective:** To determine the effect of Ivabradine in lowering heart rate and
12 quality of life in chronic heart failure patients.

13 **Methods:** The observational study was conducted in the out-patient
14 department of the National Institute of Cardiovascular Disease, Karachi, from
15 December 2016 to June 2017, and comprised chronic heart failure patients aged
16 30-70 years who were on 5mg Ivabradine for 8-weeks. Heart rate was evaluated
17 through electrocardiogram, and health-related quality of life was measured using the
18 validated questionnaire. Baseline demographics and clinical characteristics
19 were recorded, with follow-ups at week-4 and week-8. Safety and tolerability
20 were assessed by adverse drug reactions monitoring. Data was analysed using SPSS 21.

21 **Results:** Of the 50 patients, 34(68%) were males. The overall mean age was
22 54.8±9.17 years. Baseline mean heart rate significantly reduced at first and
23 second follow-up visit ($p < 0.001$). Mobility problems declined significantly as
24 well ($p < 0.05$). Health-related quality of life significantly improved on follow-
25 up visits ($p < 0.001$).

26 **Conclusion:** There was significant control of heart rate in chronic heart failure
27 patients with improvement in all parameters of quality of life.

28 **Key Words:** Heart failure, Ivabradine, Heart rate, Health-related quality of life.

Introduction

Heart failure (HF) is one of the major health challenges which affects more than 26 million people around the globe^{1,2}. The condition is highly prevalent in both western and eastern countries, and its associated co-morbidities may impair self-care behaviour, quality of life (QOL) and, thus, increase hospitalisation. The constant elevation of heart rate (HR) appears to be an independent predictor of morbidity and mortality in HF patients³.

According to the American Heart Association (AHA), the prevalence of HF in the United States is 2.2%⁴ while it varies between 1.26 and 6.7% among Asian countries⁵. Considering the local population, the disease burden has precipitated due to limited resources in recent years. Based on the data shared by the World Health Organisation (WHO), 58% of the overall death burden in Pakistan is contributed by non-communicable diseases (NCDs) of which 29% is due to cardiovascular diseases (CVDs)⁶.

Before Ivabradine approval, several classes of drugs, including beta-blockers, angiotensin-converting enzyme (ACE) inhibitor, diuretic and digoxin, were prescribed for HF management⁷. Beta-blockers are known to regulate sympathetic activity, which, by lowering HR, improves QoL in HF patients, but the use is restricted due to poor tolerance among elderly patients⁷.

Ivabradine, on the other hand, has shown better outcomes compared to beta-blockers⁸. It is administered as an add-on therapy for chronic HF patients with New York heart Association (NHYA) Class II or III, left ventricular ejection fraction (LVEF) $\leq 35\%$ and resting HR ≥ 70 beats per minute (bpm)⁹. Ivabradine lowers HR by selectively binding to I_f channel at the sino-atrial node. Its use in HF patients has significantly reduced mortality, hospitalisation and healthcare cost⁹. According to the guidelines provided by the European Society of Cardiology (ESC), administration of 5-7.5mg Ivabradine decreases the cardiovascular death risk by 17%, HF-associated mortality by 39%, and up to 30% reduction in hospitalisation rate¹⁰.

58 As there is scarcity of local literature on the efficacy of Ivabradine in Pakistani
59 population, the current study was planned to assess the effect of Ivabradine in
60 reducing HR in local HF patients and to evaluate the safety and tolerability of
61 Ivabradine by monitoring adverse drug reactions (ADRs).

62

63 **Patients and Methods**

64 The observational, single-arm, open-label study was conducted in the out-patient
65 department (OPD) of the National Institute of Cardiovascular Disease (NICVD),
66 Karachi, from December 2016 to June 2017, and comprised patients of either
67 gender aged 30-70 years with a history of chronic HF diagnosed as per the Boston
68 criteria¹¹ and the NYHA functional class II classification¹².

69 After approval from the institutional ethics review committee, the sample size
70 was calculated using the WHO software¹³ in the light of a study in which 28-day
71 mean HR reduction was 15.4 ± 10.7 ¹⁴ and by keeping 95% confidence level with
72 5% margin of error. Additional patients were recruited due to high attrition rate.

73 Those excluded were patients suffering from acute myocardial infarction (AMI),
74 cardiogenic shock severe hypotension $<90/50$ mmHg, severe hepatic
75 insufficiency, sick sinus syndrome, sino-atrial block, unstable or acute HF,
76 pacemaker dependence, unstable angina, AV-block of 3rd degree, combination
77 with strong cytochrome P450 3A4 (CYP3A4) inhibitors, and combination with
78 verapamil or diltiazem which are moderate CYP3A4 inhibitors with HR-reducing
79 properties. Moreover, patients presented with resting HR <70 bpm prior to
80 treatment were also excluded as the primary aim of the study was to assess overall
81 response rate of patients to Ivabradine in achieving HR <70 bpm. Pregnant,
82 lactating women and women of child-bearing potential not using appropriate
83 contraceptive measures were also excluded as their involvement would have led
84 to increased risk.

85 After written informed consent from the patients, baseline demographic and
86 clinical characteristics were recorded, and patients were followed up at week 4

(Visit 2) and week 8 (Visit 3). Demographic characteristics, like age, gender, body mass index (BMI), relevant medical history, risk factors, and concomitant medications, were recorded in the case report form (CRF). Ivabradine (SIVAB) 5mg was given to the patients according to their tolerability.

HR was measured through electrocardiogram (ECG) and health-related quality of life (HRQOL) was determined through EuroQoL 5-Dimensions 3-Level version (EQ-5D-3L), which is a validated questionnaire¹⁵.

The EQ-5D-3L consists of two parts. The first oart is a descriptive questionnaire which assesses five dimensions of HRQOL, including mobility, self-care, usual activities, pain or discomfort, and anxiety or depression. Each dimension is measured at 1, 2 and 3 levels, where level 1 denotes 'no problem' and level 2 and 3 indicate 'problem'¹⁵. The second part includes EuroQoL Visual Analogue Scale (EQ-VAS) that registers the self-rated health status of the respondent on the vertical VAS from 0 to 100 where 100 indicates 'best imaginable health' and 0 means 'worst imaginable health state'¹⁵. ADR severity was evaluated on the basis of Hartwig's Severity Assessment Scale¹⁶. Data was analysed using SPSS 21. Continuous variables were expressed with descriptive statistics as mean, standard deviation (SD) and 95% confidence interval (CI) for quantitative variables and as frequencies and percentages for qualitative variables. Mean difference in HR from baseline to follow-up visits was analysed using paired sample t-test and one-way analysis of variance (ANOVA) as appropriate. Differences. Improvement in EQ-VAS score from baseline to last follow-up were presented through Box and Whisker plot, including mean, range and median values. The study was duly registered¹⁷.

Results

Of the 50 patients initially enrolled, 34(68%) were males. The overall mean age was 54.8±9.17 years. Of them, 37(%) completed the study (Figure 1). Baseline characteristics of all the patients were noted and each one of them was on at least three different medications other than Ivabradine (Table 1).

Baseline mean HR significantly reduced at first and second follow-up visits ($p < 0.001$) (Table 2).

The most frequent problem reported at the baseline was issues with mobility, followed by anxiety/depression and pain/discomfort (Figure 2). While problems associated with mobility were significantly controlled ($p < 0.05$), the other variables decreased but non-significantly ($p > 0.05$). There was a significant variation in mean EQ-VAS values from baseline to visits 2 and 3 ($p < 0.05$) (Figure 3).

There was no hospitalisation or life-threatening situation with Ivabradine. Only 2(1%) patients had to discontinue the drug due to bradycardia. Dose reduction was also done 1(0,5%) patient with bradycardia. All ADRs were classified as of mild to moderate nature.

Discussion

The findings showed that Ivabradine reduced HR over 8 weeks of therapy owing to HF management as well as QOL improvement. The safety and tolerability of the study drug was also proven with minimal ADRs.

The findings are consistent with studies showing an association between HR reduction and positive QOL outcome in HF patients^{14,18}. The findings are also supported by a double-blind clinical trial involving Ivabradine which showed significant results on lowering hospitalisation rate of HF patients, reflecting on QOL and reduced healthcare costs¹⁹.

Another main QOL finding related to VAS-measured self-rated health status which improved significantly from baseline to visit 3, indicating a clear influence of Ivabradine on reducing the pathophysiologic alterations, like HR, improving mobility, and alleviating psycho-physiological constraints restricting routine activities in these patients, ultimately improving QOL^{20,21}. Therefore, as per the European Medical Agency (EMA) and the United States Food and Drug

Administration (FDA) recommendations, HR as a QOL parameter, has been included in the management of chronic HF patients^{22,23}.

Ivabradine was well-tolerated with no hospitalisation or life-threatening situation. Dose titration phenomena and discontinuation of therapy were done as per the EMA recommendations with continuous monitoring of HR to minimise the occurrence of ADRs²⁴. Although the majority of patients were taking β -blocker in combination with the study medication, it was noted during the observation period that a few patients experienced bradycardia and required dose de-escalation²⁴.

To the best of our knowledge, this is the first local study conducted to assess the tolerability and safety of Ivabradine in HF patients. The current study has several limitations, including a small sample size and its single-centre nature. However, the study does provide evidence and basis to the clinicians and healthcare providers for further research on a large scale at multiples centres to target comparative analysis in Pakistan.

Conclusion

There was significant control of HR in HF patients with improvement in all QOL parameters. Ivabradine was found to be a well-tolerated drug with minimal and controllable side effects.

Disclaimer: The Abstract was presented at CardioCon in November, 2017.

Conflict of interest: None

Source of funding: Medical Affairs Department, Getz Pharma, Karachi.

References

1. Ponikowski P, Anker SD, AlHabib KF, Cowie MR, Force TL, Hu S, et al. Heart failure: preventing disease and death worldwide. ESC Heart Fail. 2014;1(1):4-25.

2. Roger VL. Epidemiology of heart failure. *Circ Res.* 2013; 113(6):646-659.
3. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Executive summary: heart disease and stroke statistics—2016 update: a report from the American Heart Association. *Circulation.* 2016; 133(4):447-454.
4. Writing GM, Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, et al. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. *Circulation.* 2016;133(4):e38.
5. Lam CS, Teng TH, Tay WT, Anand I, Zhang S, Shimizu W, et al. Regional and ethnic differences among patients with heart failure in Asia: the Asian sudden cardiac death in heart failure registry. *Eur Heart J.* 2016; 37: 3141–3153.
6. World Health Organization. Noncommunicable Diseases (NCD) Country Profiles, [Online] 2018. [Cited 2019 Dec 10]. Available at: https://www.who.int/nmh/countries/pak_en.pdf
7. Ekman I, Chassany O, Komajda M, Böhm M, Borer JS, Ford I, et al. Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. *Eur Heart J.* 2011;32(19):2395-2404.
8. Ramires FJ, Martinez F, Gómez EA, Demacq C, Gimpelewicz CR, Rouleau JL, et al. Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas' cardiomyopathy Comment on: “Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial” by Bocchi et al. *Heart Fail.* 2018 5:1069–1071.
9. American Heart Association, Classes of heart failure. [Online] 2015. [Cited 2017 May 31]. Retrieved from: <https://www.heart.org/en/health-topics/heart-failure/what-is-heart-failure/classes-of-heart-failure>

10. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur Heart J*. 2016;37(27):2129–2200.
11. Carlson KJ, Lee DC, Goroll AH, Leahy M, Johnson RA. An analysis of physicians' reasons for prescribing long-term digitalis therapy in outpatients. *J. Chronic Dis*. 1985;38(9):733-739.
12. Dolgin M, Association NYH, Fox AC, Gorlin R, Levin RI, New York Heart Association. Criteria Committee. Nomenclature and criteria for diagnosis of diseases of the heart and great vessels. 9th ed. Boston: Little, Brown; 1994.
13. Lwanga SK, Lemeshow S, World Health Organization. Sample size determination in health studies: a practical manual. [Online] 1991; [Cited 2018 Mar 15] [Cited 2019 Dec 10]. Retrieved from: <https://apps.who.int/iris/handle/10665/40062>.
14. Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. *The Lancet*. 2010; 376(9744):875-885.
15. Van Reenen M, Oppe M. EQ-5D-3L user Guide. [Online] 2015; pp 03-04. [Cited 2018 Mar 15] Retrieved from: https://euroqol.org/wp-content/uploads/2016/09/EQ-5D-3L_UserGuide_2015.
16. Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. *Am J Hosp Pharm* 1992; 49(9): 2229–2231
17. CLinicalTrials.gov [Internet]. Effect of Ivabradine in Lowering Heart Rate and Quality of Life in Chronic Heart Failure Patients. [Updated 2018 Oct

- 229 17] [Cited 2017 Jan 19]. Available form:
230 [https://clinicaltrials.gov/ct2/show/ NCT03710057](https://clinicaltrials.gov/ct2/show/NCT03710057).
- 231 18.Reil JC, Böhm M. BEAUTIFUL results—the slower, the better?. The
232 Lancet. 2008;372(9641):779-780.
- 233 19.Tendera M, Chassany O, Ferrari R, Ford I, Steg PG, Tardif JC, et al.
234 Quality of life with ivabradine in patients with angina pectoris: the study
235 assessing the morbidity–mortality benefits of the I f inhibitor ivabradine in
236 patients with coronary artery disease quality of life substudy. Circ
237 Cardiovasc Qual Outcomes. 2016;9(1):31-38.
- 238 20.Buck HG, Dickson VV, Fida R, Riegel B, D’Agostino F, Alvaro R, et al.
239 Predictors of hospitalization and quality of life in heart failure: A model of
240 comorbidity, self-efficacy and self-care. Int J Nurs Stud.
241 2015;52(11):1714-1722.
- 242 21.Hoekstra T, Jaarsma T, van Veldhuisen DJ, Hillege HL, Sanderman R,
243 Lesman-Leegte I. Quality of life and survival in patients with heart failure.
244 Eur J Heart Fail. 2013;15(1):94-102.
- 245 22.Guideline on clinical investigation of medicinal products for the treatment
246 of chronic heart failure CPMP/EWP/235/95, Rev.2. [Updated July 20,
247 2017] [Cited 2020 April 15]. Available at:
248 [https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-chronic-heart-failure-revision-2_en.pdf)
249 [clinical-investigation-medicinal-products-treatment-chronic-heart-failure-](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-chronic-heart-failure-revision-2_en.pdf)
250 [revision-2_en.pdf](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-chronic-heart-failure-revision-2_en.pdf)
- 251 23.US Food and Drug Administration. Ivabradine (Corlanor) Label. [Updated
252 2019 April] [Cited 2020 April 15]. Available at:
253 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209964lbl.pdf
254 f
- 255 24.Bhatt AS, DeVore AD, DeWald TA, Swedberg K, Mentz RJ. Achieving a
256 maximally tolerated β -blocker dose in heart failure patients: is there room
257 for improvement? J Am Coll Cardiol. 2017;69(20):2542-2550.

Characteristics	(n=50)
Age, years	54.8±9.17
Gender	
Male	34 (68)
Female	16 (32)
Body Mass Index, Kg/m ²	28.51±5.63
BMI <25 Kg/m ²	21.27±2.32
BMI >25 Kg/m ²	30.32±4.67
Heart Rate, bpm	93.98±15.29
Systolic Blood Pressure, mmHg	130.73±21.95
Diastolic Blood Pressure, mmHg	78.37±10.85
Respiration rate, breaths per minute	17.41±1.75
Medical History	
Diabetes	18 (36)
Ischemic Cardiomyopathy	13 (26)
Dilated Cardiomyopathy	4 (8)
Hypertension	2 (4)
Alcohol user	5 (10)
Smoker	4 (8)
Others	4 (8)
Concomitant Medicine	
Anticlotting agents	49 (98)
β-Blocker	48 (96)
Statin therapy	47 (94)
Diuretic	44 (88)
ACE Inhibitor	25 (50)
ARBs	22 (44)
Anti-Anginal medication	10 (20)
Vasodilator	8 (16)

Values are given as mean ± SD or n (%)

*37 patients completed the study, four loss to follow up at week 4; two discontinued due to ADR; seven loss to follow up by week 8

SD: Standard Deviation; Bpm: Beats per minute; BMI: Body Mass Index; ACE: Angiotensin-converting enzyme; ARBs:


Angiotensin II receptor blockers

Table 1: Baseline and Clinical characteristics.

Table 2: Mean heart rate (HR) reduction from baseline to visit-3.

Heart Rate, Bpm	Mean±SD	95% CI	Mean difference	P-value
Baseline	93.98±15.29	89.58 - 98.37		
Baseline & visit 2	80.28±14.97	75.83 - 84.73	13.70*	<0.001**
Baseline & visit 3	78.81±14.25	73.98 - 83.62	15.17*	<0.001**

* Mean difference of HR is measured through Paired Sample T-test to evaluate the effect of Ivabradine
 ** P<0.005 is considered significant; One-way ANOVA is applied to calculate p-value
 S.D: Standard Deviation; Bpm: Beats per min; CI=Confidence interval



*ADRs: Adverse Drug Reaction

Figure 1: Flow chart of the study.




Figure 2: Problems reported on each visit evaluated through the EuroQol 5-dimension 3- Level (EQ-5D 3L) version.




Figure 3: EuroQol-Visual Analogue Scale (EQ-VAS) score from baseline to visit-3.